Acute Kidney Injury After TAVR: Key Risk Factors Every Cardiologist Should Know

Why It Matters

Post‑TAVR AKI markedly increases short‑ and long‑term mortality, so understanding its drivers is critical for risk stratification and procedural planning. Incorporating these predictors into clinical pathways can reduce complications and enhance value‑based care.

Key Takeaways

• 21.7% of TAVR patients develop AKI.
• Eight independent predictors identified for post‑TAVR AKI.
• Transapical access significantly raises AKI risk.
• Higher STS scores correlate with kidney injury.
• Early detection can improve survival outcomes.

Pulse Analysis

Transcatheter aortic valve replacement has become the preferred therapy for many patients with severe aortic stenosis, driven by its minimally invasive nature and expanding indications. Yet, acute kidney injury remains a frequent and serious complication, affecting roughly one in five recipients. AKI after TAVR is linked to higher in‑hospital mortality, prolonged intensive care stays, and diminished long‑term survival, making it a focal point for clinicians seeking to optimize outcomes in an aging, comorbid population.

The recent meta‑analysis pooled data from 34 international studies, revealing eight robust, independent predictors of post‑procedural AKI. Baseline comorbidities such as hypertension, coronary artery disease, peripheral vascular disease, prior stroke, and chronic kidney disease set the stage for renal vulnerability. Procedural nuances—particularly the use of transapical access and higher Society of Thoracic Surgeons risk scores—further amplify risk. These findings align with earlier, smaller investigations but provide a clearer hierarchy of factors that can be integrated into pre‑operative risk models and shared decision‑making discussions.

From a practical standpoint, the study underscores the need for proactive mitigation strategies. Optimizing volume status, minimizing contrast exposure, and favoring transfemoral over transapical approaches when feasible can blunt the AKI signal. Moreover, heightened surveillance of serum creatinine and early nephrology consultation for high‑risk patients may curtail progression to severe injury. As the evidence base matures, incorporating these predictors into standardized pathways will be essential for improving cost‑effectiveness and patient safety in the rapidly growing TAVR landscape.